Document is current
Any future updates will be listed below
-
Authors
Stegmayr, John https://orcid.org/0000-0002-8167-9259
Zetterberg, Fredrik https://orcid.org/0000-0002-7789-8782
Carlsson, Michael C.
Huang, Xiaoli
Sharma, Gunjan
Kahl-Knutson, Barbro
Schambye, Hans
Nilsson, Ulf J. https://orcid.org/0000-0001-5815-9522
Oredsson, Stina
Leffler, Hakon https://orcid.org/0000-0003-4482-8945
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (2013.0022, 2013.0022, 2013.0022)
EC | Seventh Framework Programme (HEALTH-F2-2011-256986, HEALTH-F2-2011-256986)
Vetenskapsrådet (2016-07109)
- License Information
-
More Information
Article History
Received: 23 August 2018
Accepted: 27 December 2018
First Online: 18 February 2019
Competing Interests
: F.Z. is an employee and option holder of Galecto Biotech AB (a company that develops drugs targeting galectins). H.S. is an employee and shareholder of Galecto Biotech AB. U.J.N. and H.L. are shareholders in Galecto Biotech AB. The remaining authors declare that they have no conflicts of interest with the contents of this article.
